Jazz Pharmaceuticals plc (JAZZ)

109,27 +2,17 (+2,03 %) À la clôture : 04:00PM EDT

Jazz Pharmaceuticals plc

Waterloo Exchange
Fifth Floor Waterloo Road
Dublin D04 E5W7
Ireland
353 1 634 7800
https://www.jazzpharma.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 2 800

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. Bruce C. Cozadd	Co-Founder, Chairman & CEO	2,45M	13,66M	1964
Ms. Reneé D. Galá	President & COO	1,13M	S.O.	1972
Dr. Robert Iannone M.D.	Executive VP and Global Head of Research & Development	1,08M	S.O.	1967
Mr. Philip L. Johnson	Executive VP & CFO	S.O.	S.O.	S.O.
Ms. Patricia Carr	Senior VP & Chief Accounting Officer	S.O.	S.O.	1972
Ms. Andrea N. Flynn Ph.D.	VP & Head of Investor Relations	S.O.	S.O.	S.O.
Ms. Neena M. Patil J.D.	Executive VP & Chief Legal Officer	331,61k	S.O.	1976
Ms. Heidi Manna	Executive VP & Chief People Officer	S.O.	S.O.	1972
Dr. Jed Black M.D.	Senior Vice President of Sleep & CNS Medicine	S.O.	S.O.	S.O.
Ms. Samantha Pearce	Senior Vice President of Europe & International	S.O.	S.O.	1966

Les montants ont été établis en date du 31 décembre 2022 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Jazz Pharmaceuticals plc en date du 1 avril 2024 est 3. Les scores principaux sont Audit : 6; Société : 3; Droits des actionnaires : 3; Compensation : 4.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.